Charles Duncan analyst CANTOR FITZGERALD

Currently out of the existing stock ratings of Charles Duncan, 332 are a BUY (88.53%), 38 are a HOLD (10.13%), 5 are a SELL (1.33%).

Charles Duncan

Work Performance Price Targets & Ratings Chart

Analyst Charles Duncan works at CANTOR FITZGERALD with a stock forecast success ratio of 46.5% fulfilled within 271.45 days on average.

Charles Duncan’s has documented 754 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on STOK, Stoke Therapeutics at 04-Apr-2024.

Wall Street Analyst Charles Duncan

Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS) at 7/24/2023. The price target of $145 was fulfilled within 4 days with a profit of $35.33 (32.21%) receiving and performance score of 80.54.

Average potential price target upside

ACAD ACADIA Pharmaceuticals AVXL Anavex Life Sciences Corp AXSM Axsome Therapeutics BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd CARA Cara Therapeutic CLVS Clovis Oncology CMPS Compass Pathways Plc CORT Corcept Therapeutics orporated CPRX Catalyst Pharmaceuticals CYTK Cytokinetics GERN Geron HALO Halozyme Therapeutics INO Inovio Pharmaceuticals ITCI Intracellular Th NBIX Neurocrine Biosciences NVAX Novavax OREX Orexigen Therapeutics PRTA Prothena plc RETA Reata Pharmaceuticals SAVA Cassava Sciences SGMO Sangamo Therapeutics VNDA Vanda Pharmaceuticals VYGR Voyager Therapeutics OTIC Otonomy ACOR Acorda Therapeutics AIMT Aimmune Therapeutics APTX Aptinyx AXON Axon Enterprise . LUCD Lucid Diagnostics LUMO Lumos Pharma VXRT Vaxart CLNN Clene . SEEL Seelos Therapeutics MRTX Mirati Ther ZYNE Zynerba Pharmaceuticals ADVM Adverum Biotechnologies CERE Cerevel Therapeutics Holdings DNLI Denali Therapeutics STOK Stoke Therapeutics BNOX Bionomics Ltd ADR CTIC CTi Biopharma Corp FENC Fennec Pharmaceuticals KRTX Karuna Therapeutics MRNS Marinus Pharmaceuticals ONTX Onconova Therapeutics OVID Ovid Therapeutics ZSAN Zosano Pharma Corp CRNX Crinetics Pharmaceuticals KALV Kalvista Pharmaceuticals BIVI Biovie CRDL Cardiol Therapeutics HRMY Harmony Biosciences Holdings MNMD Mind Medicine  XENE Xenon Pharmaceuticals

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

25

$7.2 (40.45%)

29

18 days ago

5/8 (62.5%)

$7.16 (40.13%)

26

Buy

30

$12.2 (68.54%)

40

30 days ago

16/19 (84.21%)

$10.44 (53.37%)

184

Buy

39

$21.2 (119.10%)

40

1 months 15 days ago

6/10 (60%)

$15.25 (64.21%)

94

Buy

33

$15.2 (85.39%)

33

1 months 15 days ago

8/19 (42.11%)

$9.25 (38.95%)

119

Buy

36

$18.2 (102.25%)

1 months 15 days ago

0/1 (0%)

$12.25 (51.58%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Charles Duncan is most bullish on?

Potential upside of $63.32 has been obtained for PRTA (PROTHENA PLC)

Which stock is Charles Duncan is most reserved on?

Potential downside of -$4.21 has been obtained for CERE (CEREVEL THERAPEUTICS HOLDINGS)

What Year was the first public recommendation made by Charles Duncan?

On 2009

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?